Category: CovidienSyndicate content

Med-tech trends: The most talked about device makers in March 2013

April 9, 2013 by Arezu Sarvestani

MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.

chart

Click to enlarge.

MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA approves 1st Type 2 diabetes drug | Wall Street Beat

April 1, 2013 by Brad Perriello

The FDA approves Johnson & Johnson's 1st-of-a-kind Invokana diabetes drug, designed to flush unabsorbed sugar from the bloodstream.

MassDevice.com Wall Street Beat

The FDA approved a 1st-of-its-kind treatment for Type 2 diabetes, Johnson & Johnson's (NYSE:JNJ) Invokana, with the federal watchdog agency citing it as a pioneer in a new class of diabetes drug.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Covidien wins $177M from Johnson & Johnson's Ethicon Endo-Surgery in ultrasound scalpel spat

March 29, 2013 by Brad Perriello

A federal judge awards $177 million to Covidien in a patent infringement lawsuit with Johnson & Johnson's Ethicon Endo-Surgery subsidiary over ultrasonic scalpel technology.

Covidien
Ethicon Endo-Surgery

UPDATED March 29, 2013, with comment from Covidien.

Hernia: Covidien's biologic mesh product hits a wall

March 8, 2013 by Brian Johnson

Covidien CFO Charles Dockendorff says there's not much room for growth in biologic tissue mesh for hernia repair, a product the company acquired in 2008.

Covidien logo

Covidien's (NYSE:COV) biologic hernia mesh product has hit a "brick wall," according to CFO Charles Dockendorff, but does that mean the company is looking to move on from the product it dropped more than $80 million to acquire?

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Covidien closes enrollment in iliac stent studies

February 21, 2013 by Sony Salzman

Covidien closes enrollment in a pair of clinical trials, Visibility and Durability, examining its iliac stents for treating peripheral artery disease.

YYmeta

Covidien (NYSE:COV) said it closed enrollment in a pair of its Visibility and Durability iliac stent clinical studies.

The prospective, multinational studies are designed to compare balloon stents with self-expanding stents in the iliac arteries for treating peripheral artery disease.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Stroke: Covidien battles "failed" clot-removing device study

February 8, 2013 by MassDevice staff

Medical device company Covidien releases 2-year study results combating a government-funded study that questioned the benefit of medical device intervention in stroke patient's future independence.

Covidien's Solitaire FR revascularization device

Medical device maker Covidien (NYSE:COV) touted 2-year study results demonstrating the safety and efficacy of its Solitaire FR revascularization system, combating another recently published study that questioned whether devices like Solitaire in provide long-term benefits to stroke patients.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

William Blair boosts NxStage stake by 20% | Wall Street Beat

February 5, 2013 by MassDevice staff

William Blair & Co. added 20% to its stake in medical device company NxStage Medical, which makes home hemodialysis equipment.

MassDevice.com Wall Street Beat

William Blair & Co. added 20% to its holdings in NxStage Medical (NSDQ:NXTM) last year, according to regulatory filings.

The Chicago-based investment bank owned more than 3.8 million NXTM shares as of Dec. 31, 2012, up 19.5% from the 3.2 million shares it owned at the close of 2011.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp